Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I / II Study Evaluating the Efficacy and Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer Who Have Failed With Standard Chemotherapy Protocols (FOLFIRINOX 3)

NCT03795311 is registered in ClinicalTrials.gov with Centre Georges Francois Leclerc as lead sponsor.

NCT NCT03795311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03795311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I / II Study Evaluating the Efficacy and Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer Who Have Failed With Standard Chemotherapy Protocols (FOLFIRINOX 3)
Lead sponsor
Centre Georges Francois Leclerc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
November 7, 2018
Completion date
July 16, 2025
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer